Sanofi

NASDAQ:SNY

Drug Manufacturers - General

Healthcare
$47.12 -0.73%

-$0.31 today

Market cap
$113.15B
Beta
0.28
P/E (TTM)
8.5
EPS (TTM)
$8.60
Dividend yield
5.62%
52W Low $41.86High $52.68

Volume 2.32M

Average 2.78M

SNY Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

SanofiNASDAQ: SNY

Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026

Cash & equivalents falls 58.7% from a year ago

Cash & equivalents stood at €6.35B at the end of Q2 FY2026, down 58.7% from a year earlier and up 14.5% from the prior quarter. Over 3 fiscal years it compounded at -15.6% a year.

Context

  • Cash & equivalents amounted to 4.9% of total assets at the end of Q2 FY2026, down 7.4 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -58.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
€6.35B+14.5% QoQ
Last fiscal yearDec 2025
€7.66B+2.9% YoY
Year agoJun 2025
€15.36B-58.7% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-58.7%——
1 year+2.9%——
3-year CAGR-15.6%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

EUR · from the balance sheet

Latest · FY2025
7.66B EUR
Year-over-year change
+2.9%
4-year CAGR
-6.7%

Cash & Equivalents vs competitors

How SNY compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -58.7% is the lowest of 11, against a peer median of -8.6%.
  • Cash & equivalents amounts to 4.9% of total assets for SNY, versus a peer median of 6.3%.
SNY Competitors
Cash & Equivalents for SNY and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NVONovo Nordisk A/SJun 2026DKK 44.48B DKK+141.3%+27.9%7.5%
AMGNAmgen Inc.Jun 2026$13.99B USD+74.3%+6.2%14.6%
LLYEli Lilly and CompanyJun 2026$8.89B USD+163.3%+51.3%6.2%
BMYBristol-Myers Squibb CompanyJun 2026$8.72B USD-30.8%+3.8%10.0%
AZNAstraZeneca PLCSep 2026$7.92B USD-2.7%-2.5%6.6%
NVSNovartis AGJun 2026$7.62B USD+14.4%+15.0%6.2%
MRKMerck & Co., Inc.Jun 2026$6.85B USD-14.5%+4.7%5.3%
SNYSanofiJun 2026€6.35B EUR-58.7%-15.6%4.9%
GILDGilead Sciences, Inc.Jun 2026$3.18B USD-38.2%+11.8%6.4%
GSKGSK plcJun 2026£3.09B GBP-37.4%-3.1%5.0%
PFEPfizer Inc.Jun 2026$976M USD-40.4%+40.0%0.5%
Peer median (excluding SNY) —-8.6%+9.0%6.3%

Competitors are the stored peer set for SNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents10.1B12.74B8.71B7.44B7.66B
Short-term Investments000486M810M
Net Receivables9.79B10.75B11.04B10.63B11.05B
Inventory8.72B8.96B9.67B9.43B10.21B
Other Current Assets1.35B870M471M13.71B307M
Total Current Assets30.56B34.03B30.66B42.59B30.95B
Property, Plant & Equipment (Net)11.98B11.68B11.81B11.6B11.51B
Goodwill48.06B49.89B49.4B43.38B41.3B
Intangible Assets21.41B21.64B24.32B22.63B26.26B
Long-term Investments2.91B3.22B3.26B3.26B6.61B
Tax Assets4.6B5.38B6.43B7.97B8.61B
Other Non-current Assets731M882M588M1.37B1.56B
Total Non-current Assets89.68B92.7B95.81B90.21B95.85B
Total Assets120.24B126.72B126.46B132.8B126.81B
Account Payables6.18B6.81B7.33B7.55B7.36B
Short-term Debt3.45B4.45B2.32B4.21B4.34B
Tax Payables309M574M597M1.13B0
Deferred Revenue319M264M000
Other Current Liabilities10.61B11.86B11.57B15.13B14.69B
Total Current Liabilities21.3B23.96B24.19B29.16B28.35B
Long-term Debt17.12B14.86B14.35B11.79B14.25B
Deferred Tax Liabilities1.62B1.84B1.86B2.17B1.67B
Deferred Revenue (Non-current)00000
Other Non-current Liabilities9.34B9B9.96B10.18B9.37B
Total Non-current Liabilities29.92B27.61B27.92B25.78B26.75B
Total Liabilities51.21B51.57B52.11B54.94B55.1B
Common Stock2.53B2.52B2.53B2.53B2.44B
Retained Earnings63.01B66.73B67.5B00
Accumulated OCI3.55B6.11B4.88B70.56B64.44B
Other Stockholders Equity0005.26B5.57B
Minority Interest350M368M313M350M334M
Total Equity69.03B75.15B74.35B77.86B71.71B
Total Debt22.41B21.21B18.7B17.91B20.33B
Net Debt12.32B8.48B9.99B10.47B12.67B

Sanofi

NASDAQ:SNY

Intrinsic Alpha fair value

Locked

Current Price

$47.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.